The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Targeting cellular pathways in glioblastoma multiforme
Open accessAbstract
Glioblastoma multiforme (GBM) is a debilitating disease that is associated with poor prognosis, short median patient survival and a very limited response to therapies. GBM has a very complex pathogenesis that involves mutations and alterations of several key cellular pathways that are involved in cell proliferation, survival, migration and angiogenesis. Therefore, efforts that are directed toward better understanding of GBM pathogenesis are essential to the development of efficient therapies that provide hope and extent patient survival. In this review, we outline the alterations commonly associated with GBM pathogenesis and summarize therapeutic strategies that are aimed at targeting aberrant cellular pathways in GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Non-Smad pathways in TGF-β signaling
Zhang, Y. E. (2009) · Cell Research · doi:10.1038/cr.2008.328 · Cited by 1,749
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Evolution of the Fgf and Fgfr gene families
Itoh, N., & Ornitz, D. M. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.08.007 · Cited by 1,096
Nevins, J. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.699 · Cited by 922
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., & Fuller, G. N. (2000) · Nature Genetics · doi:10.1038/75596 · Cited by 905
Long-term survival with glioblastoma multiforme
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., et al. (2007) · Brain · doi:10.1093/brain/awm204 · Cited by 887
The PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R., & Mills, G. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413597 · Cited by 830
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Kaina, B., Christmann, M., Naumann, S., & Roos, W. P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 663
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Lamouille, S., & Derynck, R. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611146 · Cited by 572
Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Bai, D., Ueno, L., & Vogt, P. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24748 · Cited by 529
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
VEGF Receptor Signaling in Tumor Angiogenesis
McMahon, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-3 · Cited by 519
(1997) · PubMed · Cited by 512
Land, S. C., & Tee, A. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611782200 · Cited by 507
c-Met: Structure, functions and potential for therapeutic inhibition
Ma, P. C., Maulik, G., Christensen, J., & Salgia, R. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023768811842 · Cited by 504
Structure and Function of VEGF/VEGF-receptor System Involved in Angiogenesis.
Shibuya, M. (2001) · Cell Structure and Function · doi:10.1247/csf.26.25 · Cited by 504
Shapiro, W. R., Green, S. B., Burger, P. C., Mahaley, M. S., Selker, R. G., VanGilder, J. C., Robertson, J. T., Ransohoff, J., Mealey, J., Strike, T. A., et al. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.71.1.0001 · Cited by 458
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 440
The IGF-I receptor in cell growth, transformation and apoptosis
Baserga, R., Hongo, A., Rubini, M., Prisco, M., & Valentinis, B. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00007-3 · Cited by 439
Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles
Steiniger, S. C. J., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, S. E., Uhl, R., Kock, M., Geiger, K. D., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20048 · Cited by 434
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Lokker, N. A., Sullivan, C. M., Hollenbach, S. J., Israel, M. A., & Giese, N. A. (2002) · PubMed · Cited by 429
Schuster, J., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugala, M. M., Jensen, R., Baehring, J. M., Sloan, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou348 · Cited by 422
Ohgaki, H. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-492-0_14 · Cited by 418
Ren, J., Shen, S., Wang, D., Xi, Z., Guo, L., Pang, Z., Qian, Y., Sun, X., & Jiang, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.025 · Cited by 408
Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S. M., & Barnholtz-Sloan, J. S. (2015) · Cancer Treatment and Research · doi:10.1007/978-3-319-12048-5_1 · Cited by 400
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Liu, H.-L., Hua, M.-Y., Chen, P.-Y., Chu, P.-C., Pan, C.-H., Yang, H.-W., Huang, C.-Y., Wang, J.-J., Yen, T.-C., & Wei, K.-C. (2010) · Radiology · doi:10.1148/radiol.10090699 · Cited by 393
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Akt-dependent and -independent mechanisms of mTOR regulation in cancer
Memmott, R. M., & Dennis, P. A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.004 · Cited by 382
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Self-citationPrados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371
Oncogenic EGFR Signaling Networks in Glioma
Huang, P. H., Xu, A. M., & White, F. M. (2009) · Science Signaling · doi:10.1126/scisignal.287re6 · Cited by 363
PTEN mutations in gliomas and glioneuronal tumors
Duerr, E.-M., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer-Puttlitz, B., Louis, D. N., Schramm, J., Wiestler, O. D., Parsons, R., Eng, C., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201756 · Cited by 344
Coordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways
Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321
Michaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., & Stiles, C. D. (2000) · PubMed · Cited by 310
A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo
Martens, T., Schmidt, N.-O., Eckerich, C., Fillbrandt, R., Merchant, M., Schwall, R., Westphal, M., & Lamszus, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1418 · Cited by 305
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
Abounader, R., & Laterra, J. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000050 · Cited by 300
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K. A., Wen, P. Y., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop015 · Cited by 299
A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
Yang, G., Murashige, D. S., Humphrey, S. J., & James, D. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.016 · Cited by 295
Ting, C.-Y., Fan, C.-H., Liu, H.-L., Huang, C.-Y., Hsieh, H.-Y., Yen, T.-C., Wei, K.-C., & Yeh, C.-K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.096 · Cited by 282
VEGF receptor protein–tyrosine kinases: Structure and regulation
Roskoski, R. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.121 · Cited by 269
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J.-I. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 264
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
He, G., Siddik, Z. H., Huang, Z., Wang, R., Koomen, J., Kobayashi, R., Khokhar, A. R., & Kuang, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208474 · Cited by 264
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J.-F., D'Hondt, L., Strauven, T., Chaskis, C., In't Veld, P., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 250
Zhang, M., Kleber, S., Röhrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-Villalba, A., Debus, J., Peschke, P., Wirkner, U., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1212 · Cited by 249
Hardee, M. E., Marciscano, A. E., Medina-Ramirez, C. M., Zagzag, D., Narayana, A., Lonning, S. M., & Barcellos-Hoff, M. H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0546 · Cited by 246
The natural history of EGFR and EGFRvIII in glioblastoma patients
Heimberger, A. B., Suki, D., Yang, D., Shi, W., & Aldape, K. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-38 · Cited by 235
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 232
de Groot, J. F., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F., Robins, H. I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1636 · Cited by 228
Developing Therapeutic Antibodies for Neurodegenerative Disease
Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 227
Sonoda, Y., Ozawa, T., Aldape, K. D., Deen, D. F., Berger, M. S., & Pieper, R. O. (2001) · PubMed · Cited by 224
von Deimling, A., Louis, D. N., von Ammon, K., Petersen, I., Hoell, T., Chung, R. Y., Martuza, R. L., Schoenfeld, D. A., Yaşargil, M. G., Wiestler, O. D., et al. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.77.2.0295 · Cited by 218
Izumoto, S., Tsuboi, A., Oka, Y., Suzuki, T., Hashiba, T., Kagawa, N., Hashimoto, N., Maruno, M., Elisseeva, O. A., Shirakata, T., et al. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/108/5/0963 · Cited by 217
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas
Ozawa, T., Brennan, C. W., Wang, L., Squatrito, M., Sasayama, T., Nakada, M., Huse, J. T., Pedraza, A., Utsuki, S., Yasui, Y., et al. (2010) · Genes & Development · doi:10.1101/gad.1972310 · Cited by 217
Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F., Jauch, T., Steinbrecher, A., Brawanski, A., Proescholdt, M., Schlaier, J., Buchroithner, J., et al. (2007) · Oligonucleotides · doi:10.1089/oli.2006.0053 · Cited by 215
Thiessen, B., Stewart, C., Tsao, M., Kamel-Reid, S., Schaiquevich, P., Mason, W., Easaw, J., Belanger, K., Forsyth, P., McIntosh, L., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1041-6 · Cited by 209
Singh, P., Alex, J. M., & Bast, F. (2014) · Medical Oncology · doi:10.1007/s12032-013-0805-3 · Cited by 203
TGF-β signaling and its targeting for glioma treatment.
Han, J., Alvarez-Breckenridge, C. A., Wang, Q., & Yu, J. (2015) · PubMed · Cited by 198
Uhm, J. H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J. C., Buckner, J. C., James, C. D., Scheithauer, B. W., Behrens, R. J., Flynn, P. J., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.070 · Cited by 192
Hjelmeland, M. D., Hjelmeland, A. B., Sathornsumetee, S., Reese, E. D., Herbstreith, M. H., Laping, N. J., Friedman, H. S., Bigner, D. D., Wang, X.-F., & Rich, J. N. (2004) · PubMed · Cited by 192
Quinn, J. A., Pluda, J., Dolan, M. E., Delaney, S., Kaplan, R., Rich, J. N., Friedman, A. H., Reardon, D. A., Sampson, J. H., Colvin, O. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.084 · Cited by 189
Prognostic significance of c‐Met expression in glioblastomas
Kong, D., Song, S., Kim, D., Joo, K. M., Yoo, J., Koh, J. S., Dong, S. M., Suh, Y., Lee, J., Park, K., et al. (2009) · Cancer · doi:10.1002/cncr.23972 · Cited by 187
PDGF and PDGF receptors in glioma
Nazarenko, I., Hede, S.-M., He, X., Hedrén, A., Thompson, J., Lindström, M. S., & Nistér, M. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.665097 · Cited by 183
Hjelmeland, M. D., Hjelmeland, A. B., Sathornsumetee, S., Reese, E. D., Herbstreith, M. H., Laping, N. J., Friedman, H. S., Bigner, D. D., Wang, X.-F., & Rich, J. N. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.737.3.6 · Cited by 177
Wen, P. Y., Schiff, D., Cloughesy, T. F., Raizer, J. J., Laterra, J., Smitt, M., Wolf, M., Oliner, K. S., Anderson, A., Zhu, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq198 · Cited by 173
Ma, D. J., Galanis, E., Anderson, S. K., Schiff, D., Kaufmann, T. J., Peller, P. J., Giannini, C., Brown, P. D., Uhm, J. H., McGraw, S., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou328 · Cited by 171
The tumour suppressor protein p53 can repress transcription of cyclin B
Krause, K. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.22.4410 · Cited by 171
Cho, D.-Y., Yang, W.-K., Lee, H.-C., Hsu, D.-M., Lin, H.-L., Lin, S.-Z., Chen, C.-C., Harn, H.-J., Liu, C.-L., Lee, W.-Y., et al. (2012) · World Neurosurgery · doi:10.1016/j.wneu.2011.08.020 · Cited by 166
Joensuu, H., Puputti, M., Sihto, H., Tynninen, O., & Nupponen, N. N. (2005) · The Journal of Pathology · doi:10.1002/path.1823 · Cited by 158
de Vries, N. A., Buckle, T., Zhao, J., Beijnen, J. H., Schellens, J. H. M., & van Tellingen, O. (2012) · Investigational New Drugs · doi:10.1007/s10637-010-9569-1 · Cited by 158
Prasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 156
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
Montano, N., Cenci, T., Martini, M., D’Alessandris, Q. G., Pelacchi, F., Ricci‐Vitiani, L., Maira, G., Maria, R. D., Larocca, L. M., & Pallini, R. (2011) · Neoplasia · doi:10.1593/neo.111338 · Cited by 150
Fan, C., Ting, C.-Y., Liu, H.-L., Huang, C.-Y., Hsieh, H.-Y., Yen, T., Wei, K., & Yeh, C. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.048 · Cited by 147
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Chaskis, C., Dujardin, M., Everaert, H., Lv, S., Duerinck, J., Tynninen, O., Nupponen, N. N., Michotte, A., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0402-7 · Cited by 144
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
Caraglia, M., Santini, D., Marra, M., Vincenzi, B., Tonini, G., & Budillon, A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01094 · Cited by 140
Kuppner, M. C., Hamou, M., Bodmer, S., Fontana, A., & de Tribolet, N. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420416 · Cited by 133
Hainsworth, J. D., Ervin, T. J., Friedman, E. K., Priego, V. M., Murphy, P. B., Clark, B. L., & Lamar, R. E. (2010) · Cancer · doi:10.1002/cncr.25275 · Cited by 131
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma
Koul, D., Shen, R., Kim, Y., Kondo, Y., Lu, Y., Bankson, J. A., Ronen, S. M., Kirkpatrick, D. L., Powis, G., & Yung, W. K. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop058 · Cited by 130
mTORC2 phosphorylates protein kinase Cζ to regulate its stability and activity
Li, X., & Gao, T. (2013) · EMBO Reports · doi:10.1002/embr.201338119 · Cited by 125
Lee, E. Q., Kaley, T. J., Duda, D. G., Schiff, D., Lassman, A. B., Wong, E. T., Mikkelsen, T., Purow, B. W., Muzikansky, A., Ancukiewicz, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3220 · Cited by 124
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
Gallia, G. L., Tyler, B., Hann, C. L., Siu, I., Giranda, V. L., Vescovi, A. L., Brem, H., & Riggins, G. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0680 · Cited by 121
Phase II study of PX-866 in recurrent glioblastoma
Pitz, M. W., Eisenhauer, E. A., MacNeil, M. V., Thiessen, B. A., Easaw, J. C., Macdonald, D. R., Eisenstat, D. D., Kakumanu, A. S., Salim, M., Chalchal, H. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou365 · Cited by 121
Kim, S. S., Rait, A. S., Kim, E. H., Pirollo, K. F., & Chang, E. H. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.09.005 · Cited by 118
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
Heffron, T. P., Ndubaku, C. O., Salphati, L., Alicke, B., Cheong, J., Drobnick, J., Edgar, K. A., Gould, S. E., Lee, L. B., Lesnick, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00005 · Cited by 113
Peereboom, D. M., Ahluwalia, M. S., Ye, X., Supko, J. G., Hilderbrand, S. L., Phuphanich, S., Nabors, B., Rosenfeld, M. R., Mikkelsen, T., & Grossman, S. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos322 · Cited by 109
Morrison, R. S., Yamaguchi, F., Bruner, J. M., Tang, M., Wl, M., & Berger, M. S. (1994) · PubMed · Cited by 105
FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities
Allerstorfer, S., Sonvilla, G., Fischer, H., Spiegl‐Kreinecker, S., Gauglhofer, C., Setinek, U., Czech, T., Marosi, C., Buchroithner, J., Pichler, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.61 · Cited by 105
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
Kahn, J. M., Hayman, T. J., Jamal, M., Rath, B. H., Kramp, T. R., Camphausen, K. A., & Tofilon, P. J. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not139 · Cited by 105
Marra, M., Salzano, G., Leonetti, C., Tassone, P., Scarsella, M., Zappavigna, S., Calimeri, T., Franco, R., Liguori, G., Cigliana, G., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.03.004 · Cited by 104
Lim, J.-H., Lee, E.-S., You, H. J., Lee, S. E., Park, J., & Chun, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1208003 · Cited by 100
Yunoue, S., Tokuo, H., Fukunaga, K., Feng, L., Ozawa, T., Nishi, T., Kikuchi, A., Hattori, S., Kuratsu, J., Saya, H., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209413200 · Cited by 100
A phase I/II trial of vandetanib for patients with recurrent malignant glioma
Kreisl, T. N., McNeill, K. A., Sul, J., Iwamoto, F. M., Shih, J. H., & Fine, H. A. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos265 · Cited by 96
Gerstner, E. R., Eichler, A. F., Plotkin, S. R., Drappatz, J., Doyle, C. L., Xu, L., Duda, D. G., Wen, P. Y., Jain, R. K., & Batchelor, T. T. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0390-7 · Cited by 94
Neurofibromatosis 1: closing the GAP between mice and men
Dasgupta, B., & Gutmann, D. H. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00015-1 · Cited by 94
Diversity within the pRb pathway: is there a code of conduct?
Munro, S., Carr, S. M., & Thangue, N. B. L. (2012) · Oncogene · doi:10.1038/onc.2011.603 · Cited by 94
Porru, M., Zappavigna, S., Salzano, G., Luce, A., Stoppacciaro, A., Balestrieri, M. L., Artuso, S., Lusa, S., Rosa, G. D., Leonetti, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2182 · Cited by 93
Yin, S., Girnita, A., Strömberg, T., Khan, Z., Andersson, S., Zheng, H., Ericsson, C., Axelson, M., Nistér, M., Larsson, O. S., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop008 · Cited by 92
Zhang, Y., Guessous, F., Kofman, A., Schiff, D., & Abounader, R. (2010) · PubMed · Cited by 88
Stea, B., Falsey, R. R., Kislin, K. L., Patel, J., Glanzberg, H., Carey, S. S., Ambrad, A. A., Meuillet, E. J., & Martinez, J. D. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.07.006 · Cited by 87
Wedge, S. R., & Newlands, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.203 · Cited by 84
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Kalpathy–Cramer, J., Chandra, V., Da, X., Ou, Y., Emblem, K. E., Muzikansky, A., Cai, X., Douw, L., Evans, J. G., Dietrich, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2332-5 · Cited by 84
Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
Baik, C. S., Chamberlain, M. C., & Chow, L. Q. M. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000615 · Cited by 78
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
Muhic, A., Poulsen, H. S., Mau‐Sørensen, M., Grunnet, K., & Lassen, U. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1009-y · Cited by 75
IGF-IR: a new prognostic biomarker for human glioblastoma
Maris, C., D’Haene, N., Trépant, A.-L., Mercier, M. L., Sauvage, S., Allard, J., Rorive, S., Demetter, P., Decaestecker, C., & Salmon, I. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.242 · Cited by 74
High levels of c-Met is associated with poor prognosis in glioblastoma
Petterson, S. A., Dahlrot, R. H., Hermansen, S. K., Munthe, S., Gundesen, M. T., Wohlleben, H., Rasmussen, T., Beier, C. P., Hansen, S., & Kristensen, B. W. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1723-3 · Cited by 73
Wen, P. Y., Prados, M. D., Schiff, D., Reardon, D. A., Cloughesy, T. F., Mikkelsen, T., Batchelor, T. T., Drappatz, J., Chamberlain, M. C., & de Groot, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2006 · Cited by 67
Norden, A. D., Schiff, D., Ahluwalia, M. S., Lesser, G. J., Nayak, L., Lee, E. Q., Rinne, M. L., Muzikansky, A., Dietrich, J., Purow, B. W., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1631-y · Cited by 65
MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme
Knubel, K. H., Pernu, B. M., Sufit, A., Nelson, S., Pierce, A. M., & Keating, A. K. (2014) · Oncotarget · doi:10.18632/oncotarget.1793 · Cited by 64
Reardon, D. A., Conrad, C. A., Cloughesy, T. F., Prados, M. D., Friedman, H. S., Aldape, K., Mischel, P. S., Xia, J., DiLea, C., Huang, J. M., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1854-6 · Cited by 61
Schlenska‐Lange, A., Knüpfer, H., Lange, T., Kieß, W., & Knüpfer, M. M. (2008) · PubMed · Cited by 60
Robins, H. I., Won, M., Seiferheld, W. F., Schultz, C. J., Choucair, A. K., Brachman, D. G., Demas, W. F., & Mehta, M. P. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000311 · Cited by 59
Long term responses with cetuximab therapy in glioblastoma multiforme
Belda-Iniesta, C., de Castro, J., & Sáenz, E. C. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.3118 · Cited by 58
An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Guessous, F., Zhang, Y., diPierro, C. G., Marcinkiewicz, L., Sarkaria, J. N., Schiff, D., Buchanan, S. G., & Abounader, R. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009010028 · Cited by 54
Chromosomal Instability and Phosphoinositide Pathway Gene Signatures in Glioblastoma Multiforme
Waugh, M. G. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-9034-9 · Cited by 48
Balañá, C., Gil‐Gil, M., Pérez, P., Reynés, G., Gallego, O. S., Ribalta, T., Capellades, J., González‐Ortiz, S., & Verger, E. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0305-1 · Cited by 48
Emerging immunotherapies for glioblastoma
Desai, R. R., Suryadevara, C. M., Batich, K. A., Farber, S. H., Sanchez-Perez, L. A., & Sampson, J. H. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1186643 · Cited by 46
Batchelor, T. T., Gerstner, E. R., Ye, X., Desideri, S., Duda, D. G., Peereboom, D. M., Lesser, G. J., Chowdhary, S. A., Wen, P. Y., Grossman, S. A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now185 · Cited by 46
THE SMAD PROTEINS AND TGFβ SIGNALLING: UNCOVERING A PATHWAY CRITICAL IN CANCER
Rooke, H. M., & Crosier, K. E. (2001) · Pathology · doi:10.1080/00313020123383 · Cited by 35
Lin, F., Buil, L. C. M., Sherris, D., Beijnen, J. H., & van Tellingen, O. (2013) · International Journal of Cancer · doi:10.1002/ijc.28126 · Cited by 34
Glioblastoma in a Patient with Neurofibromatosis Type 1: A Case Report and Review of the Literature
Jeong, T.-S., & Yee, G.-T. (2014) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2014.2.1.36 · Cited by 30
High Dose Tamoxifen and Radiotherapy in Patients with Glioblastoma Multiforme: A Phase IB Study
Muanza, T. M., Shenouda, G., Souhami, L., Corns, R. A., Leblanc, R., Mohr, G., & Langleben, A. (2000) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100001049 · Cited by 29
Pollack (2010) · International Journal of Oncology · doi:10.3892/ijo_00000712 · Cited by 28
Jane, E. P., Premkumar, D. R., Addo‐Yobo, S. O., & Pollack, I. F. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155705 · Cited by 28
Zhou, X., Shen, F., Ma, P., Hui, H., Pei, S., Chen, M., WANG, Z., Zhou, W., & Jin, B. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4129 · Cited by 17
Human EGFR-2, EGFR and HDAC triple-inhibitor CUDC-101 enhances radiosensitivity of GBM cells
Tandle, A. T., Schlaff, C. D., Arscott, W. T., Gordon, I. K., & Camphausen, K. (2015) · Biomedical Research Journal · doi:10.4103/2349-3666.240616 · Cited by 6
Cited by
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
Hu, H., Mu, Q., Bao, Z., Chen, Y., Liu, Y., Chen, J., Wang, K., Wang, Z., Nam, Y., Jiang, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.038 · Cited by 345
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery
Kwon, Y. W., Jo, H.-S., Bae, S., Seo, Y., Song, P., Song, M., & Yoon, J. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.747333 · Cited by 268
Metadata
- Authors
- Pearson, J. R. D., & Regad, T.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2017-09-29
- Volume
- 2
- Issue
- 1
- Pages
- 17040-17040
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W2760019720
- Cited by
- 344
- References
- 149
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.